Vitamin C-Coated stent takes on heart disease in major trial

NCT ID NCT07566091

Not yet recruiting Disease control Sponsor: Jung-min Ahn Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new stent that releases sirolimus and ascorbic acid (vitamin C) to a standard everolimus-releasing stent in over 2,000 people with coronary artery disease. The goal is to see if the new stent is as good at preventing heart-related complications like death, heart attack, or the need for repeat procedures within one year. Participants will be randomly assigned to receive one of the two stents during a routine angioplasty procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sirolimus and ascorbic acid (vitamin C) coated on a stent
What this could lead to: If successful, this could offer a new, equally effective option for opening blocked heart arteries with a stent that releases medication and vitamin C.
What could go wrong: This is a non-inferiority trial, meaning it aims to show the new stent is not worse than the standard one, not that it is better. The study hasn't started yet, and results may not show a clear advantage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

Contacts and locations

Locations

Asan Medical Center

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.